

28 July 2016

Australian Securities Exchange
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

**Alcidion appoint Resapp Health co-founder,
Brian Leedman as Non-Executive Director.**

Adelaide, South Australia, 28th July 2016 – Alcidion Group Limited (ASX: ALC), a global leader in Clinical Informatics, today announced the appointment of Mr. Brian Leedman to the board of the Company. This move comes at a pivotal time for Alcidion as the company looks to expand market share of their award-winning Miya Platform product internationally.

Mr. Leedman is the co-founder of Resapp Health (ASX:RAP) where he currently serves in the role of Executive Director and Vice President, Corporate Affairs. Mr. Leedman is a marketing and investor relations professional with over 10 years' experience in the biotechnology / healthcare industry. Prior to Resapp Health, Mr. Leedman co-founded Enigma Therapeutics which listed on the ASX in 2013 as Oncosil Medical Limited.

Mr. Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp. which is listed on the ASX and NASDAQ. He is currently the Western Australian Co-Chair of AusBiotech, the association of biotechnology companies in Australia.

"Clinical Informatics is a rapidly growing market that's critical to improve productivity, safety and efficiency across the continuum of health. Alcidion has demonstrated clear technology leadership over other players in the space and I'm excited about helping to guide the company to a broader role in the market. I believe this is the right company, at the right time, in the right market," said Mr. Leedman.

"With the drive for cost control and the new mandates surrounding EMRAM regulations, Alcidion has an ideal solution," said Mr. Leedman. "I'm looking forward to helping Alcidion expand on their track record of delivering significant improvements to patient flow."

The appointment coincides with major technical and market advancements for Alcidion, with the company recently announcing enhanced features for its award-winning Miya Platform. The new version extends the product's architecture to support Physician Order Entry and Smartforms - features key to increasing clinician productivity and mitigating clinical risk.

"Alcidion's focus is on empowering clinicians to deliver the highest quality patient care," said Nathan Buzza, Executive Director of Alcidion. "Brian's significant experience in bringing new medical technologies into the mainstream will be very important to us as we begin our next phase of growth."

Ray Blight, Chairman of Alcidion Group Limited commented, "It is my pleasure to welcome Brian to the Board of Alcidion. I'm certain through his wealth of experience and passion for the sector, he will be a valuable addition to the Board".

ENDS

For further information, please contact:

Nathan Buzza, Executive Director

Ph: +61 (0) 488862222

Alcidion Group Limited

nathan.buzza@alcidion.com

Ray Blight, Chief Executive Officer

Ph: +61 (08) 8208 4600

Alcidion Group Limited

ray.blight@alcidion.com

Brian Leedman, Non-Executive Director

Ph: +61 (0) 412 281 780

Alcidion Corporation

brian.leedman@alcidion.com

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publically listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion's solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR., Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion's focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2016. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.